title: Is TNFalpha really a good therapeutic target in motoneuronal degeneration? A case of amyotrophic lateral sclerosis in a patient with RA receiving infliximab.
authors.forename: M
authors.initials: M
authors.lastname: Dziadzio
authors.forename: V
authors.initials: V
authors.lastname: Reddy
authors.forename: S
authors.initials: S
authors.lastname: Rahman
authors.forename: C
authors.initials: C
authors.lastname: Mummery
authors.forename: A
authors.initials: A
authors.lastname: Keat
mesh_terms: D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000150:complications*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications*; D018450:Disease Progression; D006801:Humans; D000069285:Infliximab; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab